Ronald O. Perelman Purchases 1,879,700 Shares of vTv Therapeutics Inc (VTVT) Stock

vTv Therapeutics Inc (NASDAQ:VTVT) major shareholder Ronald O. Perelman purchased 1,879,700 shares of the company’s stock in a transaction dated Thursday, November 29th. The shares were acquired at an average price of $1.33 per share, for a total transaction of $2,500,001.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Shares of VTVT stock traded up $0.04 during trading hours on Friday, reaching $1.69. 213,800 shares of the company’s stock were exchanged, compared to its average volume of 1,421,310. vTv Therapeutics Inc has a 1 year low of $0.65 and a 1 year high of $8.40. The firm has a market capitalization of $64.79 million, a price-to-earnings ratio of -1.01 and a beta of -3.71.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.12) by $0.06. The business had revenue of $3.38 million for the quarter, compared to analysts’ expectations of $2.06 million. As a group, equities analysts expect that vTv Therapeutics Inc will post -0.73 earnings per share for the current year.

Separately, Zacks Investment Research lowered vTv Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, October 4th. Seven equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $13.29.

An institutional investor recently raised its position in vTv Therapeutics stock. Millennium Management LLC boosted its position in vTv Therapeutics Inc (NASDAQ:VTVT) by 51.6% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 95,031 shares of the biotechnology company’s stock after buying an additional 32,362 shares during the period. Millennium Management LLC owned approximately 0.29% of vTv Therapeutics worth $387,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 2.17% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease.

See Also: What does the Dow Jones Industrial Average (DJIA) measure?

Insider Buying and Selling by Quarter for vTv Therapeutics (NASDAQ:VTVT)

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit